In recent years there have been tremendous advances in our understanding of the circuitry of the basal ganglia and our ability to predict the behavioural effects of specific cellular changes in this circuit on voluntary movement. These advances, combined with a new understanding of the rich distribution and diverse physiological roles of metabotropic glutamate receptors in the basal ganglia, indicate that these receptors might have a key role in motor control and raise the exciting possibility that they might provide therapeutic targets for the treatment of Parkinson's disease and related disorders
Parkinson’s disease is characterized by the degeneration of dopaminergic neurons of the substantia n...
5th International Meeting on Metabotropic Glutamate Receptors, Taormina, ITALY, SEP 18-23, 2005Inter...
Restoring the balance between excitatory and inhibitory circuits in the basal ganglia, following the...
International audienceThe interplay between dopamine and glutamate in the basal ganglia regulate cri...
In the early sixties, anticholinergic drugs were introduced in the pharmacological treatment of Park...
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the loss of dopamin...
Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons of the...
Recent advances in the molecular biology of glutamate receptors have identified a family of mGluRs w...
Parkinson's disease is the slow-progressing chronic neurodegenerative disease. It caused by the prog...
The basal ganglia circuitry processes the signals that flow from the cortex, allowing the correct ex...
Glutamate overactivity within the basal ganglia has been shown to be central to the expression of mo...
International audienceCurrent therapies for treating movement disorders such as Parkinson's disease ...
Long- and short-term changes in the efficacy of synaptic transmission are known as synaptic plastici...
Parkinson’s disease is characterized by the degeneration of dopaminergic neurons of the substantia n...
5th International Meeting on Metabotropic Glutamate Receptors, Taormina, ITALY, SEP 18-23, 2005Inter...
Restoring the balance between excitatory and inhibitory circuits in the basal ganglia, following the...
International audienceThe interplay between dopamine and glutamate in the basal ganglia regulate cri...
In the early sixties, anticholinergic drugs were introduced in the pharmacological treatment of Park...
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the loss of dopamin...
Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons of the...
Recent advances in the molecular biology of glutamate receptors have identified a family of mGluRs w...
Parkinson's disease is the slow-progressing chronic neurodegenerative disease. It caused by the prog...
The basal ganglia circuitry processes the signals that flow from the cortex, allowing the correct ex...
Glutamate overactivity within the basal ganglia has been shown to be central to the expression of mo...
International audienceCurrent therapies for treating movement disorders such as Parkinson's disease ...
Long- and short-term changes in the efficacy of synaptic transmission are known as synaptic plastici...
Parkinson’s disease is characterized by the degeneration of dopaminergic neurons of the substantia n...
5th International Meeting on Metabotropic Glutamate Receptors, Taormina, ITALY, SEP 18-23, 2005Inter...
Restoring the balance between excitatory and inhibitory circuits in the basal ganglia, following the...